相关实验视频

Updated: Sep 16, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

主要胸部突肉瘤:在单一机构治疗的结果

Matthew Aizpuru¹, Samuel E Broida², Yahya Alwatari¹

¹Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota.

The Annals of thoracic surgery

|July 10, 2025

概括

主要胸部突肉瘤 (SS) 的预后不好. 完整的手术切除可以改善这些罕见的侵袭性瘤的存活率,特别是那些起源于肺部或胸壁的瘤.

科学领域:

在瘤学瘤学.
胸部外科手术胸部外科手术
肉瘤研究研究肉瘤研究

背景情况:

突肉瘤 (SS) 是一种罕见的,具有攻击性的恶性瘤,对胸部主要部位的数据有限.
这项研究解决了关于初级胸部SS.治疗结果的信息短缺问题.
描述了初级胸部SS治疗的机构经验.

研究的目的:

描述原发性胸部突肉瘤患者的治疗结果.
确定影响初级胸部SS的生存和复发的因素.
评估手术切除对患者结果的影响.

主要方法:

对43名患有初级胸部SS的患者 (1994-2022年) 的回顾性评估,不包括脊柱干扰.
收集的数据包括人口统计,瘤特征,治疗方法和结果.
生存分析使用了卡普兰-梅尔方法和考克斯比例危险模型.

主要成果:

瘤主要起源于肺部 (65%) 和胸壁 (12%).
74%的手术治疗患者实现了完全 (R0) 切除,与改善的中位数整体存活期 (46.6个月) 相关联.
与更糟糕的存活率相关的因素包括非肺起源,较大的尺寸和不完整的切除;中枢/多叶原点和尺寸≥10厘米预测复发.

结论:

主要胸部SS带来了不良的预后,肺部和胸壁起源的结果更好.
完整的手术切除 (R0) 对于改善初级胸部SS的存活率至关重要.
应强烈考虑针对负利的侵略性手术管理.

更多相关视频

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...